HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study From NHIS Data Deems Multivitamin Health Benefits As Wishful Thinking; CRN Disagrees

Executive Summary

Study by Harvard Medical researchers comparing self-reported and clinically measurable health outcomes among 4,933 MVM users and 16,670 other consumers found users self-reported 30% better overall health. CRN says the study provides only a “snapshot in time” of usage and doesn’t shed light on causality.

You may also be interested in...



Pending US Dietary Guidelines Will Consider Full Life Span, Evaluate Benefits From Supplements

Dietary Guidelines Advisory Committee notes additional guidelines for young children and pregnant women were required by language in the 2014 farm bill. “As a result, this edition will cover the full lifespan.”

More Multivitamin Research Needed To Show Disease Prevention – NIH Panel

Members of an independent NIH panel evaluating the safety and effectiveness of multivitamin/minerals (MVMs) hope that a draft report containing their recommendations will spur action on research efforts for the supplement category

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel